An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
Public ClinicalTrials.gov record NCT01753193. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Study identification
- NCT ID
- NCT01753193
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- MedImmune LLC
- Industry
- Enrollment
- 218 participants
Conditions and interventions
Conditions
Interventions
- Anifrolumab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 68 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 27, 2013
- Primary completion
- Jul 17, 2018
- Completion
- Jul 17, 2018
- Last update posted
- Jul 30, 2019
2013 – 2018
United States locations
- U.S. sites
- 23
- U.S. states
- 14
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35294 | — |
| Research Site | La Palma | California | 90623 | — |
| Research Site | Long Beach | California | 90806 | — |
| Research Site | Los Angeles | California | 90095-1670 | — |
| Research Site | Palm Desert | California | 92260 | — |
| Research Site | Upland | California | 91786 | — |
| Research Site | Ocala | Florida | 34474 | — |
| Research Site | Orlando | Florida | 32806 | — |
| Research Site | Tampa | Florida | 33614 | — |
| Research Site | Atlanta | Georgia | 30281 | — |
| Research Site | Stockbridge | Georgia | 30281 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Indianapolis | Indiana | 46202 | — |
| Research Site | Las Cruces | New Mexico | 88011 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | Charlotte | North Carolina | 28204 | — |
| Research Site | Raleigh | North Carolina | 27617 | — |
| Research Site | Columbus | Ohio | 43203 | — |
| Research Site | Tulsa | Oklahoma | 74104 | — |
| Research Site | Memphis | Tennessee | 38119 | — |
| Research Site | Houston | Texas | 77004 | — |
| Research Site | Houston | Texas | 77034 | — |
| Research Site | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01753193, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 30, 2019 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01753193 live on ClinicalTrials.gov.